FEMY
FEMASYS INC
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$1.63
−1.21%Year over year
Reported trailing growth
- Revenue
- +21.9%
- EBITDA
- +47.4%
- EBIT
- +8.3%
- EPS
- +44.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +218.3%
- EBITDA
- +67.0%
- EPS
- +66.5%
Three-year CAGR
- Revenue
- +23.9%
- EBITDA
- +2.7%
- EBIT
- +1.1%
- Net income
- +1.0%
- EPS
- +44.0%
- Free cash flow
- +4.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026